Wockhardt gains on launching generic version of Rhinitis drug

BSE 22 May 12 | 02:08 PM

684.00		18.4 (2.76%)
Mkt Price (Rs)		Chg Rs (Chg %)

Code: 532300

Face Value: N.A.

NSE 22 May 12 | 02:06 PM

689.00		22.8 (3.42%)
Mkt Price (Rs)		Chg Rs (Chg %)

Code: WOCKPHARMA

Performance
1 Week	:	Rs	676.65	(1.09%)
1 Month	:	Rs	699.30	(-2.19%)
1 Year	:	Rs	356.55	(91.84%)

Wockhardt gains on launching generic version of Rhinitis drug

SI Reporter / Mumbai 10 Jan 12 | 11:30 AM

Be the first to comment

Wockhardt has moved higher by 4% at Rs 308 after the pharmaceutical company said that it has received final approval from the USFDA for marketing nasal spray of Fluticasone which is used in treatment of allergic rhinitis.

The total market for this product in the US is about $580 million according to IMS Health, the company said in a filing to the stock exchanges.

Fluticasone nasal spray is amongst the most widely used corticosteroids in treating allergic rhinitis, it added.

The stock has opened at Rs 299 and hit a high of Rs 309 on the National Stock Exchange. A combined 321,215 shares have changed hands on the counter so far on both the exchanges.